Introduction
Taste assessment has become an important element of pharmaceutical drug development especially since paediatric regulations have been enforced in the US and EU. Evaluating the taste of new active pharmaceutical ingredients (APIs) is therefore essential to put in place adequate taste-masking techniques which will lead to appropriate palatable formulation. Thus, there is an urgent need to develop and optimise taste assessment methods that can be used at different stages of the drug development process.
Purpose
To assess the validity of the in vivo rat brief-access taste aversion (BATA) model as a screening tool for taste assessment of APIs and to compare the rat panel results with the human taste results.
Materials and Methods
Five bitter model drug substances have been selected to verify the model. The taste of 6 concentrations of quinine hydrochloride dihydrate (QHD), caffeine citrate (CC), diclofenac sodium (DS), sildenafil citrate (SC) and paracetamol (PAR) in water was assessed in ten male Sprague-Dawley rats with the BATA model (Soto et al. 2015) . Taste was assessed using the lickometer "Davis Rig MS-160", an apparatus that electronically records the number of licks that mildly water-deprived rats do to different API samples presented randomly. The taste of 4 concentrations of these same drugs was also assessed by a human taste panel conducted in 20 healthy young volunteers using the "swirl and spit" method. [UCL REC 4612/005]: 10 mL of each sample were gargled for 5 s and then expectorated. The volunteers rated the taste intensity on a Visual Analogue Scale (VAS) using the software Qualtrics.
Results
The rat data showed the same rank order of bitterness prediction (IC 50 ) as the human panel for all the drugs. Despite a slight shift between rats' and humans' responses, a good correlation (R 2 = 0.9968) was observed. Furthermore, a lower variability was observed in the rat panel. Rat BATA -Human taste panel correlation
